Loading…
UroGen Pharma Ltd. is projected to rise to $50.25 by 2027, a +29% move from its current price of $38.88. URGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $37.90 | $38.89 | $39.91 | +0.03% |
| Jul 14 | $37.50 | $38.90 | $40.35 | +0.05% |
| Jul 15 | $37.20 | $38.91 | $40.70 | +0.08% |
| Jul 16 | $36.95 | $38.92 | $40.99 | +0.10% |
| Jul 17 | $36.74 | $38.93 | $41.25 | +0.13% |
| Jul 18 | $36.55 | $38.94 | $41.49 | +0.16% |
| Jul 19 | $36.37 | $38.95 | $41.72 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $36.37 | $38.95 | $41.72 | +0.18% |
| Week 2 | $35.42 | $39.02 | $43.00 | +0.37% |
| Week 3 | $34.72 | $39.09 | $44.02 | +0.55% |
| Week 4 | $34.15 | $39.17 | $44.92 | +0.73% |
| Week 5 | $33.66 | $39.24 | $45.74 | +0.92% |
| Week 6 | $33.23 | $39.31 | $46.50 | +1.10% |
| Week 7 | $32.85 | $39.38 | $47.21 | +1.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
UroGen Pharma Ltd. is a biotechnology company focused on solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin as a general adjuvant chemotherapy option, Zusduri as a sustained-release formulation for NMIBC, and Jelmyto for pyelocalyceal solutions.
Its lead product candidates are UGN-103, in phase 3 for intravesical delivery, and UGN-104 in phase 3 for pyelocalyceal delivery, targeting several forms of non-muscle invasive urothelial cancer. UroGen has license agreements with Agenus Inc. to develop and commercialize products for urinary tract cancers via intravesical delivery, and with medac Gesellschaft für klinische Spezialpräparate m.b.H.
to develop UGN-103 and UGN-104. The company was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN is currently priced at $37.94 with a market capitalization of $1.85B and ranks 2126. The stock trades in a 30-day range of $31.98 to $45.01, reflecting a volatile backdrop consistent with biotechnology names. The 30-day technical picture shows bullish sentiment with RSI at 80, a 50-day simple moving average of $29.01 and a 200-day simple moving average of $22.74, with support at $26.54 and resistance at $37.94.
A major floor 56.3% below — a decisive break under it would weaken the trend.
The nearest floor, 31.7% below — buyers have tended to step in here.
The nearest ceiling, 3.5% above — a clean break opens room to run.
A major ceiling 25.5% above — clearing it would confirm fresh momentum.
Key URGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of URGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $38.40 | Buy | $38.48 | Buy |
| MA 10 | $37.53 | Buy | $37.47 | Buy |
| MA 20 | $35.19 | Buy | $35.44 | Buy |
| MA 50 | $30.67 | Buy | $31.32 | Buy |
| MA 100 | $25.48 | Buy | $27.70 | Buy |
| MA 200 | $23.35 | Buy | $24.06 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.29 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 92.29 | Neutral |
| Williams %R (14) | -28.55 | Info |
| MACD (12,26,9) | 0.18 | Buy |
| ROC (12) | 9.70 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 71.45 | Neutral |
| TRIX (15) | 1.14 | Buy |
| Awesome (5,34) | 6.16 | Buy |
| Ultimate (7,14,28) | 67.46 | Neutral |
| Momentum (10) | 4.18 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 39.26 | Sell |
| ADX (14) | 40.52 | Buy |
| ATR (14) | 0.86 | Info |
The near-term technical posture is bullish, supported by a strong RSI of 80. The stock trades above the SMA50 of $29.01 and the SMA200 of $22.74, suggesting positive momentum. The 30-day range spans $31.98 to $45.01, indicating upside potential beyond the current price, while a key support level sits at $26.54 and a resistance at $37.94.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $17.00 | $38.88 | $53.35 | 0% | Neutral | |
| $40.19 | $50.25 | $66.36 | +29% | Bullish | |
| $45.77 | $58.75 | $80.37 | +51% | Bullish | |
| $52.05 | $68.28 | $96.03 | +76% | Bullish | |
| $69.32 | $92.70 | $133.43 | +138% | Bullish | |
| $82.10 | $111.74 | $164.15 | +187% | Bullish | |
| $89.04 | $123.17 | $184.28 | +217% | Bullish | |
| $99.20 | $139.33 | $211.94 | +258% | Bullish | |
| $105.78 | $150.73 | $232.82 | +288% | Bullish | |
| $114.89 | $166.00 | $260.05 | +327% | Bullish | |
| $188.61 | $290.11 | $482.32 | +646% | Bullish | |
| $419.09 | $717.48 | $1,301.12 | +17.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $17.00 | $38.88 | $47.35 | +0.00% |
| August 2026 | $34.01 | $40.10 | $48.51 | +3.13% |
| September 2026 | $33.55 | $39.82 | $48.68 | -0.70% |
| October 2026 | $34.44 | $41.10 | $50.69 | +3.21% |
| November 2026 | $35.62 | $42.72 | $53.08 | +3.94% |
| December 2026 | $35.40 | $42.64 | $53.35 | -0.18% |
Click any year to see its month-by-month URGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, URGN is projected to trade between $17.00 and $53.35, averaging $38.88 — a potential gain of 0% from today's $38.88. A consolidation phase looks the most probable path here.
UroGen Pharma Ltd.'s 2027 outlook centres on $50.25, within a $40.19 to $66.36 range. That is up +29% on the projected 2026 average. That marks a +29% change versus current levels. Momentum favours further upside here.
By 2028, URGN could reach as high as $80.37, with a base case around $58.75 and support toward $45.77 — roughly +51% from $38.88. Buyers look set to stay in control over this stretch.
Expect URGN to range from $52.05 to $96.03 through 2029. The $68.28 average target implies a +76% move from current prices. That is up +16% on the projected 2028 average. Momentum favours further upside here.
The URGN price prediction for 2030 points to an average of $92.70 (low $69.32, high $133.43) — a potential gain of +138% on today's $38.88. Buyers look set to stay in control over this stretch.
In 2031, URGN is projected to trade between $82.10 and $164.15, averaging $111.74 — a potential gain of +187% from today's $38.88. That is up +21% on the projected 2030 average. Momentum favours further upside here.
UroGen Pharma Ltd.'s 2032 outlook centres on $123.17, within a $89.04 to $184.28 range. That is up +10% on the projected 2031 average. That marks a +217% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, URGN could reach as high as $211.94, with a base case around $139.33 and support toward $99.20 — roughly +258% from $38.88. Momentum favours further upside here.
Expect URGN to range from $105.78 to $232.82 through 2034. The $150.73 average target implies a +288% move from current prices. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The URGN price prediction for 2035 points to an average of $166.00 (low $114.89, high $260.05) — a potential gain of +327% on today's $38.88. Momentum favours further upside here.
In 2040, URGN is projected to trade between $188.61 and $482.32, averaging $290.11 — a potential gain of +646% from today's $38.88. That is up +75% on the projected 2035 average. Buyers look set to stay in control over this stretch.
UroGen Pharma Ltd.'s 2050 outlook centres on $717.48, within a $419.09 to $1,301.12 range. That is up +147% on the projected 2040 average. That marks a +17.5x change versus current levels. Momentum favours further upside here.
Investing $1,000 in URGN today (≈ 25.720165 URGN) could be worth
$18,453.68
+$17,453.68 (+1745%) by 2050 · US Dollar
Based on the average projected URGN price of $717.48 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in URGNwould be worth at today's price.
$1,000 invested in URGN on Jul 10, 2025 (≈ 68.306009 URGN) would be worth
$2,655.74
+$1,655.74 (+165.6%) today · 2.66× · US Dollar
Based on a URGN entry price of $14.64 vs. today's $38.88.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $38.02 | $1,022.62 | +2.3% |
| 1 month ago | $28 | $1,388.57 | +38.9% |
| 3 months ago | $21.57 | $1,802.5 | +80.3% |
| 6 months ago | $21.45 | $1,812.59 | +81.3% |
| 1 year ago | $14.64 | $2,655.74 | +165.6% |
| All time (5.0y) ago | $15.07 | $2,579.96 | +158.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our URGN forecast.
Our base-case forecast reaches $78.00 around 2030.
Implied market cap at $78.00: $3.8B
The multi-year forecast shows an upward trajectory after 2026, with the 2026 average price at $37.94 and a max of $52.01 (ROI 0). From 2027 onward, the average price climbs to $49.38 (max $65.27; ROI 30.1) and $57.74 (max $79.04; ROI 52.2) in 2028, and $66.03 (max $92.91; ROI 74) in 2029. By 2030, the average price is projected to $90.34 with a max of $130.12 (ROI 138.1); 2031–2050 show continued bullish expansion, with 2031 avg $108.95, 2032 $119.46, 2033 $137.84, 2034 $147.36, 2035 $159.54, and 2040 $282.87.
The 2040–2050 arc reaches an average of $282.87 (2040) and $694.36 (2050), with a max of $470.43 (2040) and $1,259.46 (2050). ROI figures rise from 138.1 in 2030 to 187.2 (2031), 214.9 (2032), 263.3 (2033), 288.4 (2034), 320.5 (2035), 645.6 (2040), and 1730.1 (2050). Sentiment shifts remain bullish across the longer horizon, reflecting a strong growth trajectory, albeit the figures are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $90.34 with a max of $130.12 and a min of $67.52; ROI is 138.1 and sentiment is BULLISH.
The forecast presents a bullish path from 2027 onward, with rising average prices and returns (e.g., 2027 avg $49.38, 2030 avg $90.34, 2050 avg $694.36 and max $1,259.46; ROI up to 1730.1), though 2026 is flat at a 0 ROI and these are estimates, not guarantees.
Yes. The max forecast by 2050 is $1,259.46 with an ROI of 1730.1, while the 2050 average is $694.36.
$1.85B.
UroGen Pharma Ltd. Community Discussion
0Share your UroGen Pharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.